Difference between revisions of "Part:BBa K4414026"
(17 intermediate revisions by 3 users not shown) | |||
Line 3: | Line 3: | ||
<partinfo>BBa_K4414026 short</partinfo> | <partinfo>BBa_K4414026 short</partinfo> | ||
− | This composite part consists of an N-terminal | + | This composite part consists of an N-terminal GR LBD([[Part:BBa_K4414000]]) domain and a C-terminal tetR([[Part:BBa_K4414009]]) domain fused with a GGGGGSG linker. It is designed to sense glucocorticoids and activates the transcription of the reporter gene. |
==Usage and Biology== | ==Usage and Biology== | ||
− | As a glucocorticoid sensor, this part is designed to enter the nucleus upon glucocorticoid stimulation and bind to the TCE promoter to activate downstream transcription. This part consists of a tetR DNA binding domain, which binds to the TCE promoter (BBa_K4016011) consisting of seven direct 19-bp tet operator sequence (tetO) repeats. The | + | As a glucocorticoid sensor, this part is designed to enter the nucleus upon glucocorticoid stimulation and bind to the TCE promoter to activate downstream transcription. This part consists of a tetR DNA binding domain, which binds to the TCE promoter ([[Part:BBa_K4016011]]) consisting of seven direct 19-bp tet operator sequence (tetO) repeats. The GR LBD domain on the N terminal is the ligand binding domain of the glucocorticoid receptor(GR). This LBD domain can translocate the fusion protein into the nucleus upon glucocorticoid stimulation. It also has a transactivating domain 2 (τ2) and an activation function domain 2 (AF2) which activates downstream gene expression(Weikum et al., 2017). |
<html> | <html> | ||
<figure class="figure"> | <figure class="figure"> | ||
− | <img src="https://static.igem. | + | <img src="https://static.igem.wiki/teams/4414/wiki/26-1-1.png" class="figure-img img-fluid rounded" height="350px"> |
</figure> | </figure> | ||
</html> | </html> | ||
− | Figure1. Schematic figure of BBa_K4414026 and BBa_K4414041 | + | Figure1. Schematic figure of BBa_K4414026 and ([[Part:BBa_K4414041]]) |
− | + | ||
− | + | ||
− | + | ||
+ | <!-- --> | ||
+ | ===Sequence and Features=== | ||
+ | <partinfo>BBa_K4414026 SequenceAndFeatures</partinfo> | ||
<!-- Uncomment this to enable Functional Parameter display | <!-- Uncomment this to enable Functional Parameter display | ||
Line 29: | Line 29: | ||
<!-- --> | <!-- --> | ||
− | + | ==Functional Test== | |
+ | To test the ability of this part to respond to glucocorticoids, HEK-293T cells were co-transfected with plasmids encoding both BBa_K4414026 and TCE-SEAP([[Part:BBa_K4414041]]). | ||
===Method=== | ===Method=== | ||
<html> | <html> | ||
+ | |||
+ | Cells were treated with 10, 50, or 100 nM Glucocorticoids 6 h post-transfection. Cells without glucocorticoid treatment were used as control. Culture medium was collected at 24 h or 48 h post glucocorticoids treatment. SEAP activity was measured according to a published protocol(Shao, Qiu, & Xie, 2021). | ||
+ | |||
<figure class="figure"> | <figure class="figure"> | ||
− | <img src="https://static.igem. | + | <img src="https://static.igem.wiki/teams/4414/wiki/26-2-1.png |
+ | |||
+ | |||
" class="figure-img img-fluid rounded" height="350px"> | " class="figure-img img-fluid rounded" height="350px"> | ||
Line 40: | Line 46: | ||
</html> | </html> | ||
− | + | Figure2.Schematic representation of the experimental process of validation for BBa_K4414026 and ([[Part:BBa_K4414041]]). | |
− | + | ||
− | + | ||
===Result=== | ===Result=== | ||
<html> | <html> | ||
+ | Results showed significantly increased SEAP expression in glucocorticoid-treated cells compared to the non-treated control (2-20 folds). A dose dependence was observed within 0-100 nM of glucocorticoid (Figure 3). | ||
<figure class="figure"> | <figure class="figure"> | ||
− | <img src="https:// | + | <img src="https://static.igem.wiki/teams/4414/wiki/26-3.png |
" class="figure-img img-fluid rounded" height="350px"> | " class="figure-img img-fluid rounded" height="350px"> | ||
Line 54: | Line 59: | ||
</html> | </html> | ||
− | + | Figure3. Glucocorticoid-stimulated transcriptional activation of SEAP mediated by BBa_K4414026. | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ==Reference== | |
− | + | 1. Weikum, E. R., Knuesel, M. T., Ortlund, E. A., & Yamamoto, K. R. (2017). Glucocorticoid receptor control of transcription: precision and plasticity via allostery. Nat Rev Mol Cell Biol, 18(3), 159-174. doi:10.1038/nrm.2016.152 | |
− | + | 2. Shao, J., Qiu, X., & Xie, M. (2021). Engineering Mammalian Cells to Control Glucose Homeostasis. Methods Mol Biol, 2312, 35-57. doi:10.1007/978-1-0716-1441-9_3 |
Latest revision as of 17:50, 11 October 2022
LBD-GGGGGSG-tetR
This composite part consists of an N-terminal GR LBD(Part:BBa_K4414000) domain and a C-terminal tetR(Part:BBa_K4414009) domain fused with a GGGGGSG linker. It is designed to sense glucocorticoids and activates the transcription of the reporter gene.
Usage and Biology
As a glucocorticoid sensor, this part is designed to enter the nucleus upon glucocorticoid stimulation and bind to the TCE promoter to activate downstream transcription. This part consists of a tetR DNA binding domain, which binds to the TCE promoter (Part:BBa_K4016011) consisting of seven direct 19-bp tet operator sequence (tetO) repeats. The GR LBD domain on the N terminal is the ligand binding domain of the glucocorticoid receptor(GR). This LBD domain can translocate the fusion protein into the nucleus upon glucocorticoid stimulation. It also has a transactivating domain 2 (τ2) and an activation function domain 2 (AF2) which activates downstream gene expression(Weikum et al., 2017).
Figure1. Schematic figure of BBa_K4414026 and (Part:BBa_K4414041)
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Functional Test
To test the ability of this part to respond to glucocorticoids, HEK-293T cells were co-transfected with plasmids encoding both BBa_K4414026 and TCE-SEAP(Part:BBa_K4414041).
Method
Cells were treated with 10, 50, or 100 nM Glucocorticoids 6 h post-transfection. Cells without glucocorticoid treatment were used as control. Culture medium was collected at 24 h or 48 h post glucocorticoids treatment. SEAP activity was measured according to a published protocol(Shao, Qiu, & Xie, 2021). Figure2.Schematic representation of the experimental process of validation for BBa_K4414026 and (Part:BBa_K4414041).
Result
Results showed significantly increased SEAP expression in glucocorticoid-treated cells compared to the non-treated control (2-20 folds). A dose dependence was observed within 0-100 nM of glucocorticoid (Figure 3). Figure3. Glucocorticoid-stimulated transcriptional activation of SEAP mediated by BBa_K4414026.
Reference
1. Weikum, E. R., Knuesel, M. T., Ortlund, E. A., & Yamamoto, K. R. (2017). Glucocorticoid receptor control of transcription: precision and plasticity via allostery. Nat Rev Mol Cell Biol, 18(3), 159-174. doi:10.1038/nrm.2016.152
2. Shao, J., Qiu, X., & Xie, M. (2021). Engineering Mammalian Cells to Control Glucose Homeostasis. Methods Mol Biol, 2312, 35-57. doi:10.1007/978-1-0716-1441-9_3